A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
Pancreas Cancer|Pancreas Cancer, Duct Cell Adenocarcinoma
BIOLOGICAL: AK154|BIOLOGICAL: Cadonilimab|BIOLOGICAL: Ivonescimab (SMT112 or AK112) Injection|DRUG: mFOLFORINOX
DLT, Percentage of subjects who meet the criteria of DLT in DLT observation period, Day 1 to Day 21 after the first tumour vaccine was administrated|AE, Percentage of subjects with Adverse Events (AEs), From ICF up to 30days after last study treatment
RFS, Recurrence free survival（RFS）, 2 years|OS, Overall survival（OS）, 2 years
This is a prospective, open-label, single-center, exploratory clinical study. To explore the safety, tolerability, efficacy, immunogenicity, and PK/PD profile of neoantigen personalized mRNA vaccine AK154 monotherapy or combined with AK104 or AK112, sequential mFOLFIRINOX chemotherapy regimen as postoperative adjuvant therapy in Surgically Resected Pancreatic Adenocarcino